title: Experience with BioMatrix BES and other DES in all-comers setting: a retrospective overview.
abstract: New generation DES are effectively used in all spectrum of coronary artery diseases (CAD) and are replacing earlier DES and BMS. Biolimus A9™-eluting stent is a new generation DES containing the anti-proliferative drug biolimus A9™ incorporating a biodegradable abluminal coating that leaves a polymer-free stent after drug release enhancing strut coverage while preventing neointimal hyperplasia. A retrospective data analysis was done in patients treated with DES, with a major share of Biolimus A9™ (BA9™) drug-eluting stents (DES) at Bombay Hospital, Mumbai. A total of 158 patients with 219 lesions were treated with DES, comprising Biolimus A9-eluting stent and others and the major adverse cardiac events (MACE) rate and stent thrombosis (ST) at 1, 6, 12 months and 24 months were analyzed. Mace rate was 3.16% for average follow-up of 19 months. There were 3 cases of ST (2 of acute and 1 of subacute onset) and one non-cardiac death reported during this time. This retrospective data demonstrates good one- and two-year clinical safety and efficacy of DES, especially of BioMatrix stents in real world setting.
authors.affiliation: Interventional Cardiologist, Bombay Hospital of Medical Sciences, Mumbai 400020, India; Director, Medical Education and Research, Bombay Hospital, India.
authors.forename: B K
authors.initials: BK
authors.lastname: Goyal
authors.affiliation: Interventional Cardiologist, Bombay Hospital of Medical Sciences, Mumbai 400020, India.
authors.forename: B C
authors.initials: BC
authors.lastname: Kalmath
authors.affiliation: Interventional Cardiologist, Bombay Hospital of Medical Sciences, Mumbai 400020, India.
authors.forename: Ramesh
authors.initials: R
authors.lastname: Kawar
authors.affiliation: Interventional Cardiologist, Bombay Hospital of Medical Sciences, Mumbai 400020, India.
authors.forename: Anil
authors.initials: A
authors.lastname: Sharma
authors.affiliation: Clinical Research Department, Biosensors International, Nasik 422013, India.
authors.forename: Bhushan
authors.initials: B
authors.lastname: Khemnar
authors.affiliation: Clinical Research Department, Biosensors International, Nasik 422013, India. Electronic address: h.rangnekar@biosensorsindia.com.
authors.forename: Hrishikesh
authors.initials: H
authors.lastname: Rangnekar
mesh_terms: D020341:Absorbable Implants; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000295:instrumentation / Q000379:methods / Q000401:mortality; D002423:Cause of Death; D017023:Coronary Angiography / Q000379:methods; D023903:Coronary Restenosis / Q000000981:diagnostic imaging / Q000453:epidemiology; D023921:Coronary Stenosis / Q000000981:diagnostic imaging / Q000401:mortality* / Q000628:therapy*; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007194:India; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology / Q000401:mortality; D011108:Polymers / Q000494:pharmacology; D011474:Prosthesis Design; D011475:Prosthesis Failure; D012189:Retrospective Studies; D018570:Risk Assessment; D012720:Severity of Illness Index; D012737:Sex Factors; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000494:pharmacology; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D011108:Polymers; C518022:umirolimus; D020123:Sirolimus
keywords: Abluminal; BioMatrix; Biodegradable polymer; Biolimus A9; Major adverse cardiac events